In this episode of The Atrium, host Alice Copperwheat speaks with Jessica Donington, Professor of Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago, Illinois, USA, about neoadjuvant chemoimmunotherapy.
The discussion emphasizes the importance of being upfront and honest during patient conversations. It explores the benefits of neoadjuvant chemoimmunotherapy, how patients are selected for these treatments, and the various clinical trials on this topic. The conversation also addresses the chemo-radiation route and the clinical assessment of resectability. They also examine how to determine if a tumor is resectable and what factors are assessed during this process. It also highlights the need to consider whether a planned lobectomy might necessitate a pneumonectomy following neoadjuvant chemoimmunotherapy. The conversation also covers chemotherapy, immunotherapy, and targeted therapy, outlining what trainees should remember about each. Finally, they address the complexities of neoadjuvant chemoimmunotherapy, key takeaways for trainees, and the importance of working closely with the entire multidisciplinary team throughout the process.
The Atrium is a monthly podcast presenting clinical and career-focused topics for residents and early career professionals across all cardiothoracic surgery subspecialties. Keep an eye out for next month’s episode.
Disclosure
Dr. Donington serves as an advisor, consultant, and speaker for AstraZeneca, BMS, Genentech/Roche, and Merck. Additionally, she acts as a consultant for Biodesix and an advisor for Lilly.
Disclaimer
The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
